Skip to main content
Fig. 5 | Molecular Medicine

Fig. 5

From: The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors

Fig. 5

Significantly enriched pathways associated with ERBB4 mutation in NSCLC and prognostic value of ERBB4 in pan-cancer. A Significantly enriched pathways associated with ERBB4 mutation in LUAD-TCGA cohort. B Significantly enriched pathways associated with ERBB4 mutation in LUSC-TCGA cohort. C The mutation status of ERBB4 is associated with the TMB level in pan-cancer. D The survival curves based on the mutational status of ERBB4 in pan-cancer

Back to article page

Molecular Medicine

ISSN: 1528-3658